CBMG - Cellular Biomedicine Group, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.68
+0.15 (+0.91%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close16.53
Open16.61
Bid16.00 x 1100
Ask17.75 x 1400
Day's Range16.56 - 17.02
52 Week Range10.98 - 19.86
Volume82,953
Avg. Volume53,283
Market Cap321.6M
Beta (5Y Monthly)2.62
PE Ratio (TTM)N/A
EPS (TTM)-2.43
Earnings DateFeb 19, 2020 - Feb 20, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.00
  • Cellular Biomedicine Group Announces Engagement of Independent Advisors by Special Committee
    PR Newswire

    Cellular Biomedicine Group Announces Engagement of Independent Advisors by Special Committee

    Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG") today announced that the special committee of its board of directors, composed of Alan Au, Edward Schafer, Terry A. Belmont and Wen Tao (Steve) Liu, PhD (the "Special Committee"), has retained Jefferies Group LLC as its independent financial advisor and White & Case LLP as its independent legal advisor. The Special Committee was formed to evaluate strategic alternatives for CBMG, including the preliminary non-binding proposal letter, dated November 11, 2019, submitted by a consortium led by Mr. Bizuo (Tony) Liu, the Chief Executive Officer of CBMG, certain other senior management members of CBMG, Hillhouse Bio Holdings, L.P. and TF Capital Ranok Ltd. and also including Dangdai International Group Co., Limited and Mission Right Limited, wherein the consortium has proposed to acquire all outstanding shares of common stock of CBMG (other than those shares held by the consortium members that may be rolled over in connection with the acquisition) for US$19.50 per share in cash.

  • China’s Curing Cancer Faster and Cheaper Than Anywhere Else
    Bloomberg

    China’s Curing Cancer Faster and Cheaper Than Anywhere Else

    (Bloomberg) -- Zhang Haitao was a basketball-loving teenager who dreamed of going to a specialized sports high school when he got a pain in his right arm that just wouldn’t go away. It turned out to be acute lymphoblastic leukemia.The discovery set Zhang and his family, from a village deep in the mountains of southwestern China's Sichuan province, on a journey familiar to most cancer patients — a revolving door of hospital visits, blood tests and three rounds of chemotherapy. It was then that Zhang’s doctor suggested a last-ditch option: an experimental gene therapy being trialed by a Chinese startup called Gracell Biotechnology Ltd.After spending three weeks in the hospital in May — during which white blood cells were removed from his body, genetically engineered, and then infused back in — an analysis of Zhang’s bone marrow in June showed his body was clear of cancer.Seven months later, monthly medical tests conducted at a hospital in the nearby Chinese metropolis of Chongqing show he remains cancer free. “I don’t remember much about the treatment as I had a fever throughout,” said Zhang, who’s now almost 16 and spends his days playing video games and texting his friends. “It seems like a new solution that will give people hope.”Read more about how China is overhauling its healthcare systemThe therapy Zhang received was Chimeric Antigen Receptor-T cells, known as CAR-T, and it’s being hailed as one of the most exciting developments in the quest to cure cancer. First developed by Israeli scientist Zelig Eshhar in the 1980s, CAR-T re-works the genes of the body’s own immune cells so that they actively seek out and destroy cancer cells. While it’s been embraced by researchers and drugmakers around the world, perhaps nowhere is CAR-T having more impact — and being pushed dangerously close to its limits — than in China, home to the world’s biggest cancer population and some of the most ambitious experiments.CAR-T works by supercharging T-cells, the body’s main line of defense against disease, so that they latch onto and destroy cancer. In clinical trials, leukemia patients who failed to respond to other therapies have shown remission rates of over 90% within two months of treatment.Though drug giants Novartis AG and Gilead Sciences Inc. have been marketing CAR-T globally since 2017, it’s expensive. The process of engineering an individual’s cells in a laboratory and then replicating them has also meant that some patients with more aggressive cancers can die waiting for treatment.That’s where Gracell’s therapy was revolutionary. Instead of the two to three weeks taken by current treatments from American and European drug makers, the Shanghai-based company — set up by a group of veteran Chinese cell-therapy researchers — is churning out cancer-killing immune cells overnight.And they’re doing it much cheaper in some cases than global pharmaceutical giants. Gracell has developed a process using genetic engineering that speeds up the cell production stage, according to founder William Cao Wei. Gracell plans to price its CAR-T treatment for about 500,000 yuan ($71,000), well below the $475,000 price tag for Novartis’ Kymriah, the Swiss company’s CAR-T therapy used to treat the type of blood cancer that Zhang had. A similar treatment from Gilead, based in Foster City, California, costs $373,000.The aging population and a raft of lifestyle factors mean that more new cancer patients are emerging in China than anyplace else in the world, giving the country a significant stake in the global fight to find a cure. Emboldened by the government’s push to become a scientific superpower and to dominate the field of genetics, Gracell and other Chinese biotech startups are racing ahead, with China likely to approve CAR-T for widespread use as early as next year. Up for grabs is a market for cancer drugs and experimental treatments that has exploded to $133 billion a year worldwide, according to life sciences researcher Iqvia Institute.“There can be both cooperation and competition between us and CAR-T developers in developed markets,” said Cao, who is also Gracell’s chief executive officer. “But there will definitely be competition.” That drive to forge ahead — and in front — can be seen in the way China is approaching regulation of CAR-T. The country is weighing new rules that would loosen oversight of the revolutionary technology, allowing academic ethics committees within hospitals to approve new CAR-T treatments and then administer them to patients for a fee.That would markedly loosen China’s current framework, which is presently in line with the approach taken by regulatory bodies like the U.S Food and Drug Administration and the European Medicines Agency. These entities are the sole authorities in their jurisdictions that evaluate and approve all CAR-T therapies before they are cleared for public use.There is concern among researchers, regulatory experts and drugmakers themselves that allowing hospitals to market treatments for a fee could cause profit-making to trump ethical considerations. In a 2016 case widely reported in the Chinese media, a 22-year-old college student with a rare type of tissue cancer called synovial sarcoma died after going through an experimental cell therapy at a Beijing hospital.“Hospitals can become both players and referees at the same time”Before his death, the patient posted an essay online claiming the hospital had falsely advertised the treatment’s effectiveness, and that Chinese search engine Baidu Inc. had displayed the hospital’s advertising so that it appeared like a credible search result rather than a paid commercial. The essay went viral and sparked an outcry on Chinese social media over the ethics of private hospitals and the regulation of therapies for serious illnesses.Censured by the Cyberspace Administration of China, Baidu responded by restricting the number of sponsored posts to 30% of a results page, and established a 1 billion yuan fund to fight fraud. The hospital did not respond to requests for comment.It’s not the only death allegedly linked to genetic cell therapy in China. Last year, a hospital in the eastern city of Xuzhou was sued over the death of a lymphoma patient who died after receiving a CAR-T treatment. The patient developed severe side effects, including bleeding within the abdomen. The patient’s family argued that the treatment led to his death, but the hospital and doctor said it was the result of late-stage cancer. A court is yet to rule on the case.China’s proposed new framework is reminiscent of its wider approach to the regulation of science, an area President Xi Jinping has prioritized as part of his ambition to cement the country as a world power.The research of He Jiankui, an American-educated Chinese scientist whose revelation last year that he’d edited the genes of twin baby girls ignited a global firestorm, was signed off by the ethics committee of a Shenzhen hospital. The experiment, which He claimed made the twins immune to HIV, wasn’t backed by peer-reviewed data and still hasn’t been verified. Scientists around the world have condemned it as an irresponsible use of a technology that has the capacity to alter the very building blocks of life. The long-term effects of Crispr, the gene-snipping tool used by He and embraced by Chinese researchers, are also yet to be fully understood.China’s new draft rules on CAR-T could give rise to the same scenario, critics say.There’s no guarantee that the hospital committees have the qualifications to evaluate such a complicated therapy, said Tao Xin, a Washington, D.C.-based lawyer at Hogan Lovells LLP who specializes in the health-care regulatory law of both the U.S. and China.“The proposal indicates that hospitals can charge a fee for the therapy, in addition to approving its own therapy,” he said. “With these two combined, are we going to see a replay of the 2016 incident? If there’s money to be made and I get to decide whether to do it or not, that’s really controversial.”Read about how Crispr is being used in China’s quest to make a super pigGracell’s Cao is also critical of the new framework as it removes the role of an independent entity that evaluates the therapy’s safety and efficacy: “Hospitals can become both players and referees at the same time.”Novartis and Gilead declined to comment on China’s regulatory plans, while a spokesman for the National Health Commission, the body in charge of governing the country’s health sector, said that the proposed new rules are still under discussion.Read about how Chinese parents are using DNA tests to map out their children’s livesMeanwhile, Chinese companies are racing ahead on CAR-T and attracting hundreds of millions of dollars from investors like Singapore’s sovereign wealth fund Temasek Holdings Pte Ltd, as well as global pharmaceutical giants. Venture capital investment in Chinese biotech firms climbed to $17.6 billion last year, quadruple the amount from 2015, according to consultancy ChinaBio LLC. Gracell — which counts Temasek and Lilly Asia Ventures, the venture capital firm spun off from Eli Lilly & Co. as investors — says 32 of the 35 patients it’s enrolled in its China-based trials over the past year have gone into complete remission “with minimal residual disease tested negative” four weeks after the CAR-T infusion — a clinical term that basically means there was no evidence of disease remaining in their bodies, the highest possible efficacy level for a therapy.Other Chinese startups like Nanjing Legend, a unit of Hong Kong-listed Genscript Biotech Corp., and U.S.-listed Cellular Biomedicine Group Inc., have developed similar capabilities.In 2018, Novartis paid $40 million for a 9% stake in Shanghai-based Cellular Biomedicine, and will use their cell therapy facility to manufacture its Kymriah treatment, which is currently being assessed for approval by China’s drug regulator. The startup is also developing its own CAR-T therapies and testing their potential against solid tumors, not just blood cancers. Chief Executive Officer Tony Liu Bizuo said Cellular Biomedicine’s digitized and automated process cuts the cell engineering time from four weeks to less than 10 days.Cellular Biomedicine is now mulling building a bigger cell production facility with the Shanghai government, as demand for cell therapy grows and on expectations more commercial CAR-T treatments will be approved in China in the coming years. In a sign of the support startups are getting from the authorities, the city’s government has earmarked a 4 million square feet space for cell therapy research. Of the 21 cell therapies currently in clinical trials approved by China’s drug regulator, 11 are being conducted in the lab, which is fast becoming the nation’s CAR-T Ground Zero.The next frontier is to make CAR-T as accessible as any other drug, and Chinese startups are at the leading edge. Dubbed “universal CAR-T,” this involves finding a way to take T-cells from healthy people and engineering them so that they can be infused into any cancer patient. Gracell is studying the use of donor white blood cells, marking a step toward that goal. Other startups like French company Cellectis SA are also racing to make universal CAR-T a reality.“I’m very impressed with the pace of technological progress in China and the expansion of CAR-T research coming so rapidly,” said Bruce Levine, a professor specializing in cancer gene therapy at the Perelman School of Medicine at the University of Pennsylvania.“We all want these therapies to move fast and some are very good, but we need to be aware that some could be moving too fast for their expertise, even if they have very good intentions,“ he said.Read about how a Chinese genetics giant wants to tailor drugs to people’s DNAAfter a year in and out of hospital, Zhang, the teenage cancer patient in Chongqing, is starting to make plans for the future. If it wasn’t for the leukemia, he’d be in his first year of high school now.“I don’t think I can go to sports school anymore, but I hope to learn a professional skill,” said Zhang, who’s now a foot taller than his aunt, Chen Chunhua, his primary caregiver. “I want to grasp this chance I have.”While China’s approach to CAR-T may be criticized as moving too fast, Chen, who left her job at a ceramics factory to care for Zhang when he got sick, is thankful he had access to the treatment, which wouldn’t have been possible in China had the boy fallen ill just a year earlier.“I’m so happy we had this option within China,” she said. “It really helps to lessen our burden.”  \--With assistance from Dong Lyu.To contact the editor responsible for this story: Rachel Chang at wchang98@bloomberg.net, Anjali CordeiroFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Cellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T, at the 61st Annual Meeting of the American Society of Hematology
    PR Newswire

    Cellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T, at the 61st Annual Meeting of the American Society of Hematology

    Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies, announced early data from its ongoing investigator initiated trial ("IIT") at an oral presentation titled "Novel Anti-BCMA CAR-T for Relapsed or Refractory Multiple Myeloma" at the 61st American Society of Hematology ("ASH") annual meeting on December 7, 2019 in Orlando, Florida.

  • This Hedge Fund Bought Cellular Biomedicine Group, Inc. (CBMG) At The Right Time
    Insider Monkey

    This Hedge Fund Bought Cellular Biomedicine Group, Inc. (CBMG) At The Right Time

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]

  • Thomson Reuters StreetEvents

    Edited Transcript of CBMG earnings conference call or presentation 6-Nov-19 9:30pm GMT

    Q3 2019 Cellular Biomedicine Group Inc Earnings Call

  • Zacks Small Cap Research

    CBMG: Data from Multiple Myeloma Trial to be Presented at ASH…

    By David Bautz, PhD NASDAQ:CBMG READ THE FULL CBMG RESEARCH REPORT Business Update Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) is a biopharmaceutical company developing cell-based therapies for cancer and degenerative diseases. The company is currently conducting investigator-initiated trials (IIT) in China for two of its chimeric antigen receptor (CAR)-T products as well as a T Cell Receptor

  • Cellular Biomedicine Group Announces Receipt of a Preliminary Non-Binding "Going Private" Proposal
    PR Newswire

    Cellular Biomedicine Group Announces Receipt of a Preliminary Non-Binding "Going Private" Proposal

    NEW YORK and SHANGHAI , Nov. 11, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development ...

  • Cellular Biomedicine Group Reports Third Quarter of 2019 Financial Results and Business Highlights
    PR Newswire

    Cellular Biomedicine Group Reports Third Quarter of 2019 Financial Results and Business Highlights

    NEW YORK and SHANGHAI , Nov. 6, 2019 /PRNewswire/ --  Cellular Biomedicine Group Inc.  (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development ...

  • Cellular Biomedicine Group to Report Third Quarter 2019 Results on November 6, 2019
    PR Newswire

    Cellular Biomedicine Group to Report Third Quarter 2019 Results on November 6, 2019

    NEW YORK and SHANGHAI , Oct. 30, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development ...

  • Is Cellular Biomedicine Group (NASDAQ:CBMG) A Risky Investment?
    Simply Wall St.

    Is Cellular Biomedicine Group (NASDAQ:CBMG) A Risky Investment?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

  • Cellular Biomedicine Group Announces New Facility to Expand Research and Development and to Support Clinical Development
    PR Newswire

    Cellular Biomedicine Group Announces New Facility to Expand Research and Development and to Support Clinical Development

    - Executing long-term strategy to support clinical development of multiple cell therapy platform technologies in the United States NEW YORK and SHANGHAI , Oct. 2, 2019 /PRNewswire/ --  Cellular Biomedicine ...

  • Cellular Biomedicine Group to Present at the 2019 Cantor Global Healthcare Conference
    PR Newswire

    Cellular Biomedicine Group to Present at the 2019 Cantor Global Healthcare Conference

    NEW YORK and SHANGHAI , Oct. 1, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc.  (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development ...

  • Zacks Small Cap Research

    CBMG: Initiating Coverage of Cellular Biomedicine Group; Multiple Cell-Based Therapies to Treat Cancer and Degenerative Diseases…

    By David Bautz, PhD NASDAQ:CBMG READ THE FULL CBMG RESEARCH REPORT Initiating Coverage We are initiating coverage of Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) with a valuation of $24.00. Cellular Biomedicine Group is a biopharmaceutical company developing cell-based therapies for cancer and degenerative diseases, with a focus on the Chinese

  • Cellular Biomedicine Group's ReJoin® Therapy Receives Stem Cell Drug Application Acceptance For Phase II Clinical Trials by China NMPA
    PR Newswire

    Cellular Biomedicine Group's ReJoin® Therapy Receives Stem Cell Drug Application Acceptance For Phase II Clinical Trials by China NMPA

    SHANGHAI and NEW YORK , Sept. 27, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the development ...

  • Cellular Biomedicine Group Hosts Meeting with Investigators to Launch AlloJoin® Knee Osteoarthritis Phase II Clinical Trial
    PR Newswire

    Cellular Biomedicine Group Hosts Meeting with Investigators to Launch AlloJoin® Knee Osteoarthritis Phase II Clinical Trial

    - First stem cell drug application accepted in China to conduct Phase II Clinical Trial - Orthopedic Doctors representing six class 3AAA hospitals (most specialized) NEW YORK and SHANGHAI , Sept.12, 2019 ...

  • Cellular Biomedicine Group to Present at 5th Annual CAR-TCR Summit in Boston
    PR Newswire

    Cellular Biomedicine Group to Present at 5th Annual CAR-TCR Summit in Boston

    NEW YORK and SHANGHAI , Sept. 9, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc.  (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development ...

  • Cellular Biomedicine Group to Present at Baird's 2019 Global Healthcare Conference
    PR Newswire

    Cellular Biomedicine Group to Present at Baird's 2019 Global Healthcare Conference

    NEW YORK and SHANGHAI , Aug. 29, 2019 /PRNewswire/ --  Cellular Biomedicine Group Inc.  (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development ...

  • Should You Be Pleased About The CEO Pay At Cellular Biomedicine Group, Inc.'s (NASDAQ:CBMG)
    Simply Wall St.

    Should You Be Pleased About The CEO Pay At Cellular Biomedicine Group, Inc.'s (NASDAQ:CBMG)

    Tony Liu has been the CEO of Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) since 2016. First, this article will...

  • Thomson Reuters StreetEvents

    Edited Transcript of CBMG earnings conference call or presentation 6-Aug-19 8:30pm GMT

    Q2 2019 Cellular Biomedicine Group Inc Earnings Call

  • Cellular Biomedicine Group Inc (CBMG) Q2 2019 Earnings Call Transcript
    Motley Fool

    Cellular Biomedicine Group Inc (CBMG) Q2 2019 Earnings Call Transcript

    CBMG earnings call for the period ending June 30, 2019.

  • Cellular Biomedicine Group Reports Second Quarter and First Half of 2019 Financial Results and Business Highlights
    PR Newswire

    Cellular Biomedicine Group Reports Second Quarter and First Half of 2019 Financial Results and Business Highlights

    - Began enrollment for the second cohort in a dose escalation clinical study in multiple myeloma for CBMG's anti-BCMA CAR-T asset. Submitted pre-IND meeting application to the NMPA. - Readied patients ...

  • Cellular Biomedicine Group to Report Second Quarter 2019 Results on August 6, 2019
    PR Newswire

    Cellular Biomedicine Group to Report Second Quarter 2019 Results on August 6, 2019

    NEW YORK and SHANGHAI , July 23, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development ...

  • If You Had Bought Cellular Biomedicine Group (NASDAQ:CBMG) Stock Three Years Ago, You Could Pocket A 25% Gain Today
    Simply Wall St.

    If You Had Bought Cellular Biomedicine Group (NASDAQ:CBMG) Stock Three Years Ago, You Could Pocket A 25% Gain Today

    Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) shareholders might be concerned after seeing the share price drop 13...

  • ­Cellular Biomedicine Group Executives to Present at CAR-TCR Summit Asia
    PR Newswire

    ­Cellular Biomedicine Group Executives to Present at CAR-TCR Summit Asia

    NEW YORK and SHANGHAI , June 18, 2019 /PRNewswire/ --  Cellular Biomedicine Group Inc . (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development ...